Pipeline

Print Text Size

Sanofi's Complete R&D Portfolio

Sanofi’s research focuses on finding innovative solutions to major public health challenges, including rare diseases, diabetes, immunology. cancer, multiple sclerosis and more.



With science and patients at the center of what we do, Sanofi Genzyme continues to focus on developing scientific approaches and novel therapies for complex and debilitating diseases.

Explore our pipeline to see highlights of our research programs in various stages of clinical development.

Items marked with ^ are being developed in collaboration with Regeneron and a * are being developed in collaboration with Alnylam®. Items shown with a † denote a Phase 2/3 trial.

Filter View
Technology The platform or technologic approach upon which a treatment is based; either chemically synthesized like a small molecule or polymer drug, or biologic like a protein, antibody, or cell therapy.
Phase I Clinical trials on small number of human subjects, usually healthy, primarily to assess safety and potential side effects at different dosages.
Phase II Clinical trials on affected patients, primarily to test efficacy; usually randomized and placebo-controlled.
Phase III Clinical trials on affected patients to further test efficacy, benefits, and potential side effects; usually randomized, placebo-controlled, and blinded.
Immunology
Dupilumab^
Asthma
mAb
Phase III
Dupilumab^
Eosinophilic esophagitis
mAb
Phase II
Dupilumab^
Nasal Polyposis
mAb
Phase II
Sarilumab^
Uveitis
mAb
Phase II
Oncology
Isatuximab
Multiple Myeloma

monoclonal antibody

Phase III
PD-1 Inhibitor^
Cutaneous Squamous Cell Carcinoma

mAb

Phase II
Rare Diseases
Patisiran*
hATTR Amyloidosis
RNAi
Phase III
NeoGAA
Pompe disease, 2nd generation enzyme
protein-based therapy
Phase III
Olipudase Alfa†
Acid Sphingomyelinase Deficiency (ASMD)
protein-based therapy
Phase II
Oral CGS Inhibitor
Fabry disease
small molecule
Phase II
Fitusiran*
Hemophilia
RNAi
Phase II
Oral CGS Inhibitor
Parkinson's disease with a GBA mutation
small molecule
Phase II
Oral CGS Inhibitor
Gaucher Type 3
small molecule
Phase II
Multiple Sclerosis
GLD52
Multiple Sclerosis
mAb
Phase I

The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.

In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Lebers congenital amaurosis type 1. We have several programs in multiple sclerosis with molecules addressing areas of unmet need, using approaches such as immunomodulation, neuroprotection, and remylination.

genzyme
Last Updated: 7/12/2017
GZUS.GZ.16.10.2192(5)
infoBox